The trial is taking place at:

American Oncology Network | Zangmeister Cancer Center

Veeva-enabled site

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

Gilead Sciences logo

Gilead Sciences

Status and phase

Phase 3


Triple Negative Breast Cancer
PD-L1 Negative


Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel
Drug: Gemcitabine
Drug: nab-Paclitaxel
Drug: Carboplatin

Study type


Funder types



2021-005743-79 (EudraCT Number)
CTR20234162 (Registry Identifier)
DOH-27082022-7958 (Registry Identifier)
jRCT2041220122 (Registry Identifier)

Details and patient eligibility


The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.


540 estimated patients




18+ years old


No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Individuals, regardless of race and ethnic group, with previously untreated locally advanced, inoperable or metastatic triple-negative breast cancer (TNBC)

    • Individuals whose tumors are programmed cell death ligand 1 (PD-L1) negative at screening or individuals whose tumors are PD-L1 positive at screening if they have received an anti-PD-(L)1 inhibitor in the (neo) adjuvant setting or if they cannot be treated with a checkpoint inhibitor due to a comorbidity
    • Centrally confirmed TNBC and PD-L1 status on fresh or archival tissue
    • Individuals must have completed treatment for Stage I-III breast cancer, if indicated, and ≥ 6 months must have elapsed (with the exception of endocrine therapy) between completion of treatment with curative intent and first documented local or distant disease recurrence
    • Individuals presenting with de novo metastatic TNBC are eligible
  • Measurable disease based on computed tomography (CT) or magnetic resonance imaging (MRI) in accordance with per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. as evaluated locally

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

  • Demonstrates adequate organ function

  • Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception

  • Individuals with human immunodeficiency virus (HIV) must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease

Key Exclusion Criteria:

  • Positive serum pregnancy test or women who are lactating
  • Received systemic anticancer treatment within the previous 6 months or radiation therapy within 2 weeks prior to enrollment
  • Have not recovered from adverse events (AEs) due to a previously administered agent at the time study entry
  • May not be participating in a study with an investigational agent or investigational device within 4 weeks prior to randomization. Individuals participating in observational studies are eligible
  • Previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a topoisomerase inhibitor
  • Active second malignancy
  • Active serious infection requiring antibiotics
  • Positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease
  • Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial design

Primary purpose




Interventional model

Parallel Assignment


None (Open label)

540 participants in 2 patient groups

Sacituzumab Govitecan-hziy (SG)
Experimental group
Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle.
Drug: Sacituzumab Govitecan-hziy
Treatment of Physician's Choice (TPC)
Active Comparator group
Participants will receive TPC determined prior to randomization from 1 of the 3 allowed regimens: * Paclitaxel 90 mg/m\^2 on Days 1, 8, and 15 of a 28-day cycle * Nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 of a 28-day cycle * Gemcitabine 1000 mg/m\^2 + carboplatin area under the curve (AUC) 2 on Days 1 and 8 of a 21-day cycle
Drug: Carboplatin
Drug: nab-Paclitaxel
Drug: Gemcitabine
Drug: Paclitaxel

Trial contacts and locations



Central trial contact

Gilead Clinical Study Information Center

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems